NYSEAMERICAN:OSTX OS Therapies Q2 2024 Earnings Report $1.74 -0.05 (-2.79%) Closing price 06/9/2026 04:10 PM EasternExtended Trading$1.78 +0.04 (+2.41%) As of 06:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast OS Therapies EPS ResultsActual EPS-$0.26Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOS Therapies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOS Therapies Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile OS Therapies Earnings HeadlinesOS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic OsteosarcomaJune 2, 2026 | finanznachrichten.deOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”May 28, 2026 | businesswire.comThe tiny chipmaker set to supply Musk 5 billion chipsSpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsoft, Amazon, or Google. Tech expert and angel investor Jeff Brown has identified one chipmaker, 148 times smaller than NVIDIA, that is set to supply Musk with 5 billion chips over the next two years. Brown brings decades of senior executive experience at Qualcomm, Juniper Networks, and NXP Semiconductors to this call.June 10 at 1:00 AM | Brownstone Research (Ad)OS Therapies Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical AdvisorMay 15, 2026 | finanznachrichten.deOS Therapies (OSTX) price target increased by 16.67% to 14.28May 15, 2026 | msn.comSee More OS Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email. Email Address About OS TherapiesOS Therapies (NYSEAMERICAN:OSTX), a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.View OS Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The J.M. Smucker Company’s Dividend: Too Sweet to Ignore?Has Temu-Owner PDD's Story Changed After Double Miss?Campbell's Soup Stock: Deep Value and a 7% Dividend YieldTanker Dividends Are Surging, But Income Investors Need to Watch the CycleCybersecurity Earnings: 1 AI Standout and 2 Stocks Under PressureThese 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? Upcoming Earnings Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
